MedTrace Logo

Study of ONO-8539 in Patients With Overactive Bladder

NCT00876421 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 435

Last updated 2012-06-14

No results posted yet for this study

Summary

The objective of this study is to investigate efficacy, safety and tolerability of ONO-8539 in patients with overactive bladder.

Conditions

Interventions

DRUG

Placebo

Placebo / 12 weeks

DRUG

Tolterodine

4mg / 12 weeks

DRUG

ONO-8539

low dose / 12 weeks

DRUG

ONO-8539

medium dose / 12 weeks

DRUG

ONO-8539

higher dose / 12 weeks

Sponsors & Collaborators

  • Ono Pharmaceutical Co. Ltd

    lead INDUSTRY

Principal Investigators

  • Tomohiro Kuwayama · Clinical Development, ONO Pharma UK, Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-04-30

Countries

  • Czechia
  • Germany
  • Hungary
  • Netherlands
  • Poland
  • Romania
  • Russia
  • Sweden
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00876421 on ClinicalTrials.gov